Company intelligence / Profile preview

Immatics US, Inc.

Houston, Texas, United States

Ownership: Private
Employees: ~700
Development stage: Other

Overview

Immatics has advanced a broad PRAME-focused franchise with both T cell receptor engineered T cell therapies (TCR-T) and TCR bispecifics. Its lead program (anzutresgene autoleucel, targeting PRAME) is in Phase 3 for melanoma and has shown strong anti-tumor activity and durability in metastatic melanoma in recent studies. The company is actively enrolling in multiple ongoing clinical trials and has multiple assets in Phase 1 and preclinical stages[1][3][4].

Therapeutic areas: Oncology
Modalities: T cell receptor engineered T cell therapyBispecific monoclonal antibody
Industry: Biotech

Drug pipeline

12 assets

IMA901

11 more assets in the full pipeline.

Request access →

Partnerships

Bristol Myers SquibbGenmab

Beyond the preview

Go deeper on Immatics US, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Immatics US, Inc..

Explore the full profile